Literature DB >> 19383912

FOXP3 defines regulatory T cells in human tumor and autoimmune disease.

Ilona Kryczek1, Rebecca Liu, Guobin Wang, Ke Wu, Xiaogong Shu, Wojciech Szeliga, Linhua Vatan, Emily Finlayson, Emina Huang, Diane Simeone, Bruce Redman, Theodore H Welling, Alfred Chang, Weiping Zou.   

Abstract

Activated T cells may express FOXP3. It is thought that FOXP3 is not a specific marker to determine regulatory T cells (Treg) in humans. Here, we examined the functional phenotype and cytokine profile of the in vitro induced FOXP3(+) T cells, primary FOXP3(+) and FOXP3(-) T cells in patients with ulcerative colitis and tumors including colon carcinoma, melanoma, hepatic carcinoma, ovarian carcinoma, pancreatic cancer, and renal cell carcinoma. We observed similar levels of suppressive capacity of primary FOXP3(+) T cells in blood, tumors, and colitic tissues. Compared with primary FOXP3(-) T cells in the same microenvironment, these primary FOXP3(+) T cells expressed minimal levels of effector cytokines, negligible amount of cytotoxic molecule granzyme B, and levels of suppressive molecules interleukin-10 and PD-1. Although the in vitro activated T cells expressed FOXP3, these induced FOXP3(+) T cells expressed high levels of multiple effector cytokines and were not functionally suppressive. The data reinforce the fact that FOXP3 remains an accurate marker to define primary Tregs in patients with cancer and autoimmune disease. We suggest that the combination of FOXP3 and cytokine profile is useful for further functionally distinguishing primary Tregs from activated conventional T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383912     DOI: 10.1158/0008-5472.CAN-08-3804

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  75 in total

Review 1.  The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4(+) FoxP3(+) regulatory T cells.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Immunology       Date:  2011-06-02       Impact factor: 7.397

2.  Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Stephan Lang; Theresa L Whiteside
Journal:  J Immunol Methods       Date:  2011-04-13       Impact factor: 2.303

Review 3.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

Review 4.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

Review 5.  Considerations for successful cancer immunotherapy in aged hosts.

Authors:  V Hurez; Á S Padrón; R S Svatek; T J Curiel
Journal:  Clin Exp Immunol       Date:  2016-11-07       Impact factor: 4.330

6.  Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.

Authors:  Suresh Kalathil; Amit A Lugade; Austin Miller; Renuka Iyer; Yasmin Thanavala
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701

7.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

8.  Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.

Authors:  M M Imanguli; E W Cowen; J Rose; S Dhamala; W Swaim; S Lafond; B Yagi; R E Gress; S Z Pavletic; F T Hakim
Journal:  Leukemia       Date:  2014-02-28       Impact factor: 11.528

9.  IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

Authors:  Geok Choo Sim; Natalia Martin-Orozco; Lei Jin; Yan Yang; Sheng Wu; Edwina Washington; Deborah Sanders; Carol Lacey; Yijun Wang; Luis Vence; Patrick Hwu; Laszlo Radvanyi
Journal:  J Clin Invest       Date:  2014-01       Impact factor: 14.808

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.